FDA grants Breakthrough Therapy Designation to Kadmon's KD025 for cGVHD
Kadmon announced the FDA has granted Breakthrough Therapy Designation to KD025, the company’s ROCK2 inhibitor, for treatment of patients with chronic graft-versus-host disease after failure of two or more lines of systemic therapy. Kadmon is currently enrolling patients in a pivotal Phase 2 trial. October 17, 2018